Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL1741208 Target Snapshot

NACHT, LRR and PYD domains-containing protein 3 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,145Compounds
470Assays
2Approved Drugs
1,211.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-14

NACHT, LRR and PYD domains-containing protein 3 shows clinical signal disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q96P20. Start with COVID-19, then reuse UniProt Q96P20 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with COVID-19, then reuse UniProt Q96P20 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-14 1 linked drug
Open source guide
Disease program
COVID-19

NACHT, LRR and PYD domains-containing protein 3 shows clinical signal disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with COVID-19 because it currently carries clinical signal support. Linked drugs include DAPANSUTRILE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Clinical signal Open Targets-ready proxy 1 linked drug
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats NACHT, LRR and PYD domains-containing protein 3 as ChEMBL target CHEMBL1741208, mapped to UniProt Q96P20. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
NACHT, LRR and PYD domains-containing protein 3
SINGLE PROTEIN · Homo sapiens
As of 2026-09-14
ChEMBL target ID
CHEMBL1741208
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-14
www.ebi.ac.uk
UniProt accession
Q96P20
NACHT, LRR and PYD domains-containing protein 3
UniProt accession via ChEMBL component mapping As of 2026-09-14
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-14
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether NACHT, LRR and PYD domains-containing protein 3 is the right protein anchor across sources, using UniProt Q96P20 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why COVID-19 is currently framed as clinical signal support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameNACHT, LRR and PYD domains-containing protein 3
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ96P20
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNACHT, LRR and PYD domains-containing protein 3
UniProt AccessionQ96P20
Component TypeProtein
Sequence Length1036 aa

NACHT, LRR and PYD domains-containing protein 3

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as NACHT, LRR and PYD domains-containing protein 3, mapped to UniProt Q96P20. Sequence length is 1036 aa.

Mapped IDQ96P20
Review nameNACHT, LRR and PYD domains-containing protein 3
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Clinical signal Open Targets-ready proxy

NACHT, LRR and PYD domains-containing protein 3 shows clinical signal disease relevance led by COVID-19. 5 more disease programs remain visible in the same review block.

Clinical signal Phase II
COVID-19
1 linked drug · 1 direct · 1 efficacy
Linked drugDAPANSUTRILE
Clinical signal Phase II
Schnitzler syndrome
1 linked drug · 1 direct · 1 efficacy
Linked drugDAPANSUTRILE
Clinical signal Phase II
type 2 diabetes mellitus
1 linked drug · 1 direct · 1 efficacy
Linked drugDAPANSUTRILE
Clinical signal Phase I
melanoma
1 linked drug · 1 direct · 1 efficacy
Linked drugDAPANSUTRILE
Clinical signal Phase I
systolic heart failure
1 linked drug · 1 direct · 1 efficacy
Linked drugDAPANSUTRILE
Mechanism-linked
myocardial infarction
1 linked drug · 1 direct · 1 efficacy
Linked drugDAPANSUTRILE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with COVID-19 because it currently carries clinical signal support. Linked drugs include DAPANSUTRILE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseaseCOVID-19
Strongest levelClinical signal
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

2
Approved
2
Phase III
4
Phase II
3
Phase I
Assay Mix

Activity Type Distribution

IC501,110.0
EC5062.0
KD39.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5419955 10.15 IC50 0.07 Preclinical
CHEMBL5408007 9.82 IC50 0.15 Preclinical
CHEMBL5429355 9.52 IC50 0.3 Preclinical
CHEMBL5409389 9.49 IC50 0.32 Preclinical
CHEMBL5435222 9.42 IC50 0.38 Preclinical
CHEMBL5414596 9.4 IC50 0.4 Preclinical
CHEMBL5422139 9.4 IC50 0.4 Preclinical
CHEMBL5426651 9.4 IC50 0.4 Preclinical
CHEMBL5408740 9.3 IC50 0.5 Preclinical
CHEMBL5425624 9.3 IC50 0.5 Preclinical
Distribution

pChEMBL Value Distribution

208
5.0
181
5.5
100
6.0
78
6.5
75
7.0
62
7.5
53
8.0
14
8.5
22
9.0
2
9.5
pChEMBL
Assay Landscape

Assay Landscape

470
Total Assays
664
Tested Compounds
3
Assay Types
Binding — 467 assays, 664 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 326 494 6.5
single protein format 61 42 6.4
tissue-based format 51 78 6.1
assay format 22 30 5.4
subcellular format 6 0 —
organism-based format 1 20 5.3
Functional — 2 assays, 68 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 2 68 5.3
ADME — 1 assays, 0 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 1 0 —

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine